Use Of Cannabinoids In The Treatment Of Epilepsy

Abstract

The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).


Claims
Owners (US)
CPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Apr 24, 2018
  • Application: Mar 3, 2017
    US US 201715449185 A
  • Priority: Mar 3, 2017
    US US 201715449185 A
  • Priority: Oct 4, 2016
    US US 201615284766 A
  • Priority: Jun 17, 2015
    US US 201514741783 A
  • Priority: Apr 17, 2015
    GB GB 201506550 A
  • Priority: Jun 17, 2014
    GB GB 201410771 A

Sign in to the Lens